Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Vertex Pharmaceuticals



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1%. By the end of trading, Vertex Pharmaceuticals rose 91 cents (1.6%) to $59.04 on heavy volume. Throughout the day, 3.1 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of two million shares. The stock ranged in a price between $57.49-$59.50 after having opened the day at $58.19 as compared to the previous trading day's close of $58.13. Other companies within the Health Care sector that increased today were:

Dehaier Medical Systems



), up 59.1%,

MEI Pharma



), up 34%,

Halozyme Therapeutics



), up 24%, and

SunLink Health Systems



), up 19%.

TheStreet Recommends

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $12.5 billion and is part of the


industry. The company has a P/E ratio of 29.2, below the average drugs industry P/E ratio of 30.3 and above the S&P 500 P/E ratio of 17.7. Shares are up 74.3% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now